- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Nintedanib Chemo Combo Promising for Malignant Mesothelioma
June 5th 2017, 10:50pm
Frontline treatment with nintedanib plus pemetrexed and cisplatin improved progression-free survival by 3.7 months for chemotherapy-naive patients with malignant pleural mesothelioma, according to data reported at the 2017 ASCO Annual Meeting.
Nivolumab Alone or With Ipilimumab Controls Disease, Extends Survival, in Mesothelioma
June 5th 2017, 9:31pm
Nivolumab as monotherapy or in combination with ipilimumab may present a new second- or third-line treatment option for patients with malignant pleural mesothelioma, based on preliminary findings from a phase II trial where nivolumab alone or in the combination improved disease control and prolonged survival in patients with this rare but aggressive cancer.
Alectinib Delayed Progression, Reduced Risk for Death by 53% in ALK+ NSCLC
June 5th 2017, 8:48pm
In patients with ALK-positive non-small cell lung cancer, the second-generation TKI inhibitor alectinib (Alecensa) delayed progression by an additional 15 months compared with the standard-of-care crizotinib (Xalkori).
Pembrolizumab Again Demonstrates Durable Activity in TNBC
June 5th 2017, 7:01pm
Pembrolizumab (Keytruda) showed durable antitumor activity in patients with heavily pretreated metastatic triple-negative breast cancer (TNBC), according to findings from cohort A of the phase II KEYNOTE-086 trial presented at the 2017 ASCO Annual Meeting.
Dr. Tolaney on Activity With Abemaciclib in Patients With HR+/HER2- Breast Cancer
June 5th 2017, 4:43am
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the results of a phase II trial exploring the efficacy of abemaciclib as a treatment of brain metastases that are secondary in patients with hormone receptor (HR)-positive,HER2-negative breast cancer.
Dr. Sharman on the Phase III Results of the GENUINE Study in CLL
June 5th 2017, 4:09am
Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).
Pembrolizumab Gastric Cancer Data Updated, as FDA Considers Approval
June 5th 2017, 2:03am
Pembrolizumab continued to show promising signs of clinical activity as a treatment for patients with advanced gastric or gastroesophageal junction cancer in updated findings from the KEYNOTE-059 study.
Nivolumab/Ipilimumab Highly Active in Patients With Melanoma Brain Metastases
June 5th 2017, 12:27am
Nivolumab plus ipilimumab demonstrated an intracranial response rate of 42% in asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.
Lenalidomide Consolidation OS Plateau Intrigues in CLL
June 4th 2017, 11:25pm
Induction therapy with fludarabine and rituximab followed by lenalidomide consolidation therapy (FR-L) demonstrated a distinct plateau in overall survivalbeyond that seen with FR or FR plus cyclophosphamide (FCR) alone for patients with symptomatic, untreated non-del(11q) chronic lymphocytic leukemia.
Patients With Advanced Cancer Live Longer When They Report Symptoms Online and in Real Time
June 4th 2017, 10:00pm
Patients receiving treatment for metastatic cancer who used a web-based tool to report their symptoms either while at home or during clinic visits lived on average 5 months longer than their counterparts who had standard symptom monitoring, according to findings of a randomized trial reported at the 2017 ASCO Annual Meeting.
Study Backs 50% Chemo Cutback After Surgery for Low-Risk Colon Cancer
June 4th 2017, 9:57pm
Most patients with low-risk advanced colon cancer would benefit from a 50% reduction in the oxaliplatin-containing chemotherapy they typically receive after surgery without notably increasing their risk of recurrence and while markedly decreasing the likelihood that they will develop neuropathy, according to an analysis that challenges the current standard of care and paves the way for a more personalized approach.
Lenvatinib OS Noninferior, PFS Improved Versus Sorafenib for Unresectable HCC
June 4th 2017, 9:26pm
First-line treatment with lenvatinib (Lenvima) improved progression-free survival by 3.7 months and was noninferior for overall survival compared with sorafenib for patients with unresectable hepatocellular carcinoma.
Dr. Soberman on the Next Generation of Multidisciplinary Care
June 4th 2017, 8:17pm
Mark S. Soberman, MD, MBA, FACS, was elected as the 2017-2018 President of the Association of Community Cancer Centers (ACCC) discusses his vision for the next generation of multidisciplinary care in an interview during the 2017 ASCO Annual Meeting.
Olaparib Extends PFS in Phase III BRCA+ Breast Cancer Trial
June 4th 2017, 6:52pm
The PARP inhibitor olaparib (Lynparza) reduce the risk of disease progression by 42% versus standard chemotherapy in patients with BRCA-positive, HER2-negative breast cancer, according to findings from the phase III OLYMPIAD trial.
Pembrolizumab/Entinostat Active in Melanoma Patients Refractory to Checkpoint Inhibitors
June 4th 2017, 6:35pm
Combining the PD-1 inhibitor pembrolizumab (Keytruda) with the HDAC inhibitor entinostat demonstrated promising clinical activity and acceptable safety in patients with melanoma who were refractory to immune checkpoint inhibitors.
Ublituximab/Ibrutinib Shows High ORR for High-Risk CLL
June 4th 2017, 4:30am
The combination of ublituximab and ibrutinib demonstrated an objective response rate of 78% for patients with previously treated high-risk chronic lymphocytic leukemia.
Dr. Apolo on Updated JAVELIN Results of Avelumab in Urothelial Carcinoma
June 4th 2017, 4:21am
Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses the updated findings of the phase Ib JAVELIN trial exploring avelumab (Bavencio) for the treatment of patients with metastatic urothelial carcinoma.
Genomic Profiling Yields OS Benefit for Patients With Targeted Therapy Matches
June 4th 2017, 3:12am
Comprehensive genomic testing is not yet widespread, but a French study presented at the 2017 ASCO Annual Meeting suggested that DNA profiling can be of important value in advancing personalized medicine.
Dr. Attai on the Challenges With Implementing Survivorship Care Plans
June 4th 2017, 1:50am
Deanna J. Attai, MD, assistant clinical professor of surgery at the David Geffen School of Medicine at the University of California Los Angeles (UCLA), breast surgeon at UCLA Health, discusses studies exploring the challenges with survivorship care plan implementation for patients with cancer in an interview during the 2017 ASCO Annual Meeting.
Larotrectinib Yields Impressive Responses Across All Age Groups and Tumor Types Harboring TRK Fusion Mutations
June 4th 2017, 1:16am
Three out of 4 patients representing a range of TRK fusion–positive solid tumors responded to the novel pan-TRK inhibitor larotrectinib (LOXO-101) and remain on treatment, setting the stage for the well-tolerated oral agent to become a standard of care for adults and children with any advanced tumor harboring this mutation.